The British Medical Association (BMA) Cymru, which represents thousands of doctors in Wales, says its members are already reporting incidents where they say they witnessed the safety of patients ...
PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...
Marcel Imwinkelried, Chief Executive Officer Siegfried: “Aligned with Siegfried's strategy EVOLVE+, the new lab facility marks a key milestone in DINAMIQS' journey to becoming the leading CDMO in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback